RIG-I activation is critical for responsiveness to checkpoint blockade, and RIG-I activating immunostimulatory RNA boosts the efficacy of anti-cancer vaccines and synergizes with immune checkpoint blockade (51, 52). This evidence concerns the gene RIGI and cancer.